Mandelblatt, Jeanne S.
Cai, Ling
Luta, George
Kimmick, Gretchen
Clapp, Jonathan
Isaacs, Claudine
Pitcher, Brandeyln
Barry, William
Winer, Eric
Sugarman, Stephen
Hudis, Clifford
Muss, Hyman
Cohen, Harvey J.
Hurria, Arti
Clinical trials referenced in this document:
Documents that mention this clinical trial
Frailty and long-term mortality of older breast cancer patients: CALGB 369901 (Alliance)
https://doi.org/10.1007/s10549-017-4222-8
Cognitive function and discontinuation of adjuvant hormonal therapy in older breast cancer survivors: CALGB 369901 (Alliance)
https://doi.org/10.1007/s10549-017-4353-y
Funding for this research was provided by:
National Institutes of Health (RO1CA127617, R35CA197289, RO1CA129769, RO1CA124924, KO5CA96940)
Article History
Received: 23 March 2017
Accepted: 24 March 2017
First Online: 31 March 2017
Compliance with ethical standards
:
: Gretchen Kimmick—Consultant to Genomic Health, AstraZeneca, Novartis, Pfizer. Claudine Isaacs—Honoraria from Genentech and Pfizer; Advisory board for AstraZeneca. Arti Hurria—Consulting services for Boehringer Ingelheim, Carevive, Sanofi, GTx Inc, and Perian Biosciences and research funding from Novartis, Celegene, and GSK. All other authors declares that they have no conflict of interest.